Cargando…

Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Sgherza, Nicola, Curci, Paola, Strafella, Vanda, Rizzi, Rita, Musto, Pellegrino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mattioli 1885 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182598/ https://www.ncbi.nlm.nih.gov/pubmed/33988136 http://dx.doi.org/10.23750/abm.v92i2.11395

Ejemplares similares

SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

P-159: Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma
por: Sgherza, Nicola, et al.
Publicado: (2022)

Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study
por: Sgherza, Nicola, et al.
Publicado: (2021)

COVID-19 in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): An Observational Retrospective Study
por: Sgherza, Nicola, et al.
Publicado: (2021)

Humoral Immune Response after anti-SARS-CoV-2 Vaccine “Booster” Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)
por: Sgherza, Nicola, et al.
Publicado: (2023)

P63 BREAKTHROUGH COVID-19 IN FULL VACCINATED PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE OF 54 PATIENTS
por: Sgherza, N., et al.
Publicado: (2023)

SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance
por: Sgherza, Nicola, et al.
Publicado: (2022)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by AB0 blood group in subjects with transfusion-dependent thalassemia
por: Sgherza, Nicola, et al.
Publicado: (2022)

Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study
por: Weber, Brittany N, et al.
Publicado: (2021)

Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells
Publicado: (1994)

“Hemolysis, or not Hemolysis, that is the Question”. Use of Hydroxychloroquine in a Patient with COVID-19 Infection and G6PD Deficiency
por: Sgherza, Nicola, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Assessing the importance of interleukin-6 in COVID-19
por: Chen, Luke Y C, et al.
Publicado: (2021)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19
por: Garbers, Christoph, et al.
Publicado: (2021)

Systemic IL-6 and Severe Asthma
por: Lipworth, Brian, et al.
Publicado: (2020)

Role of IL-6 in Severe Inflammation
por: Inoue, Ken-ichiro, et al.
Publicado: (2021)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Investigation of Genetic Variations of IL6 and IL6R as Potential Prognostic and Pharmacogenetics Biomarkers: Implications for COVID-19 and Neuroinflammatory Disorders
por: Strafella, Claudia, et al.
Publicado: (2020)

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
por: D’Agostino, Mattia, et al.
Publicado: (2021)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 – Authors' reply
por: Bovijn, Jonas, et al.
Publicado: (2021)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

COVID-19: Clean up on IL-6
por: Hedrick, Tanner L., et al.
Publicado: (2020)

Assessing the importance of interleukin-6 in COVID-19 – Authors' reply
por: Leisman, Daniel E, et al.
Publicado: (2021)

Special issue on Interleukin-6 (IL-6)
por: Rincon, Mercedes
Publicado: (2012)

Preemptive interleukin-6 blockade in patients with COVID-19
por: Guillén, Lucía, et al.
Publicado: (2020)

Rethinking interleukin-6 blockade for treatment of COVID-19
por: Scherger, S., et al.
Publicado: (2020)

P29: EFFECTS OF VACCINATION ON INCIDENCE AND OUTCOME OF SARS-COV-2 INFECTION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS)
por: Sgherza, N, et al.
Publicado: (2022)

Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
por: Harmer, Danielle, et al.
Publicado: (2019)

Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells
por: Lin, Xuanru, et al.
Publicado: (2017)

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity
por: Ray, Arghya, et al.
Publicado: (2019)

Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?
por: Musto, Pellegrino
Publicado: (2018)

Is IL-6 the Right Target in COVID-19 Severe Pneumonia?
por: Blot, Mathieu, et al.
Publicado: (2021)

Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019
por: Huang, Lan, et al.
Publicado: (2020)

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
por: Piccolomo, Antonio, et al.
Publicado: (2020)

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
por: Mina, Roberto, et al.
Publicado: (2020)

Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_0hl1t6kiok93h0ra8gl9c3lg66